These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 38819948

  • 1. Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients.
    Ceccarelli F, Picciariello L, Natalucci F, Moretti V, Spinelli FR, Alessandri C, Conti F.
    Clin Exp Rheumatol; 2024 Jul; 42(7):1491-1494. PubMed ID: 38819948
    [Abstract] [Full Text] [Related]

  • 2. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
    Gatto M, Saccon F, Zen M, Regola F, Fredi M, Andreoli L, Tincani A, Urban ML, Emmi G, Ceccarelli F, Conti F, Bortoluzzi A, Govoni M, Tani C, Mosca M, Ubiali T, Gerosa M, Bozzolo E, Canti V, Cardinaletti P, Gabrielli A, Tanti G, Gremese E, De Marchi G, De Vita S, Fasano S, Ciccia F, Pazzola G, Salvarani C, Negrini S, Puppo F, Di Matteo A, De Angelis R, Orsolini G, Rossini M, Faggioli P, Laria A, Piga M, Mathieu A, Scarpato S, Rossi FW, de Paulis A, Brunetta E, Ceribelli A, Selmi C, Prete M, Racanelli V, Vacca A, Bartoloni E, Gerli R, Larosa M, Iaccarino L, Doria A.
    Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
    [Abstract] [Full Text] [Related]

  • 3. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, Tsalapaki C, Pantazi L, Konsta S, Mavragani CP, Dimopoulou D, Ntali S, Katsikas G, Boki KA, Vassilopoulos D, Konstantopoulou P, Liossis SN, Elezoglou A, Tektonidou M, Sidiropoulos P, Erden A, Sfikakis PP, Bertsias G, Boumpas DT.
    Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
    [Abstract] [Full Text] [Related]

  • 4. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity.
    Jesus D, Matos A, Henriques C, Zen M, Larosa M, Iaccarino L, Da Silva JAP, Doria A, Inês LS.
    Ann Rheum Dis; 2019 Mar; 78(3):365-371. PubMed ID: 30626657
    [Abstract] [Full Text] [Related]

  • 5. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.
    BMJ Open; 2019 Mar 20; 9(3):e025687. PubMed ID: 30898822
    [Abstract] [Full Text] [Related]

  • 6. Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study.
    Su Z, Zhang C, Gao C, Li C, Li R, Zheng Z.
    Arthritis Res Ther; 2024 Sep 18; 26(1):163. PubMed ID: 39294688
    [Abstract] [Full Text] [Related]

  • 7. Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health-Related Quality of Life.
    Jesus D, Henriques C, Matos A, Doria A, Inês LS.
    Arthritis Care Res (Hoboken); 2024 Jun 18; 76(6):788-795. PubMed ID: 38258369
    [Abstract] [Full Text] [Related]

  • 8. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
    Nikoloudaki M, Nikolopoulos D, Koutsoviti S, Flouri I, Kapsala N, Repa A, Katsimbri P, Theotikos E, Pitsigavdaki S, Pateromichelaki K, Bertsias A, Elezoglou A, Sidiropoulos P, Fanouriakis A, Boumpas D, Bertsias G.
    Front Immunol; 2022 Jun 18; 13():1074044. PubMed ID: 36685524
    [Abstract] [Full Text] [Related]

  • 9. The effect of systemic lupus erythematosus (SLE) Disease Activity Score and SLE Disease Activity Index 2000-based remission states in patients with SLE on damage accrual.
    Chitpet P, Chaiamnuay S, Narongroeknawin P, Asavatanabodee P, Leosuthamas P, Pakchotanon R.
    Int J Rheum Dis; 2023 Dec 18; 26(12):2509-2516. PubMed ID: 37875327
    [Abstract] [Full Text] [Related]

  • 10. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.
    Parodis I, Johansson P, Gomez A, Soukka S, Emamikia S, Chatzidionysiou K.
    Rheumatology (Oxford); 2019 Dec 01; 58(12):2170-2176. PubMed ID: 31157891
    [Abstract] [Full Text] [Related]

  • 11. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.
    Touma Z, Sayani A, Pineau CA, Fortin I, Matsos M, Ecker GA, Chow A, Iczkovitz S.
    Rheumatol Int; 2017 Jun 01; 37(6):865-873. PubMed ID: 28280970
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2017 May 01; 69(5):1016-1027. PubMed ID: 28118533
    [Abstract] [Full Text] [Related]

  • 13. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
    Ginzler E, Guedes Barbosa LS, D'Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, Santiago MB, Saxena A, Sheikh S, Bass DL, Burriss SW, Gilbride JA, Groark JG, Miller M, Pierce A, Roth DA, Ji B.
    Arthritis Rheumatol; 2022 Jan 01; 74(1):112-123. PubMed ID: 34164944
    [Abstract] [Full Text] [Related]

  • 14. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
    Cunha RN, Saraiva L, Jesus D, Doria A, da Silva JP, Inês LS.
    Rheumatology (Oxford); 2023 Nov 02; 62(11):3627-3635. PubMed ID: 36847423
    [Abstract] [Full Text] [Related]

  • 15. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
    Ramirez GA, Canti V, Moiola L, Magnoni M, Rovere-Querini P, Coletto LA, Dagna L, Manfredi AA, Bozzolo EP.
    Int J Rheum Dis; 2019 Sep 02; 22(9):1752-1761. PubMed ID: 31379114
    [Abstract] [Full Text] [Related]

  • 16. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials.
    Touma Z, Gladman DD, Ibañez D, Taghavi-Zadeh S, Urowitz MB.
    J Rheumatol; 2011 Nov 02; 38(11):2395-9. PubMed ID: 21885488
    [Abstract] [Full Text] [Related]

  • 17. A Comparison of the Correlation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) with Health-Related Quality of Life.
    Lai NS, Lu MC, Chang HH, Lo HC, Hsu CW, Huang KY, Tung CH, Hsu BB, Wu CH, Koo M.
    J Clin Med; 2021 May 15; 10(10):. PubMed ID: 34063379
    [Abstract] [Full Text] [Related]

  • 18. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS).
    Abdelhady EI, Rabie M, Hassan RA.
    Clin Rheumatol; 2021 Nov 15; 40(11):4553-4558. PubMed ID: 34142298
    [Abstract] [Full Text] [Related]

  • 19. Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients.
    Jesus D, Rodrigues M, Matos A, Henriques C, Pereira da Silva JA, Inês LS.
    Lupus; 2019 Apr 15; 28(5):607-612. PubMed ID: 30895904
    [Abstract] [Full Text] [Related]

  • 20. Real-world efficacy of belimumab in achieving remission or low-disease activity in systemic lupus erythematosus: A retrospective study.
    Hasegawa Y, Arinuma Y, Asakura H, Shindo R, Ino K, Kanayama Y, Tanaka T, Matsueda Y, Wada T, Oku K, Yamaoka K.
    Mod Rheumatol; 2024 Jul 06; 34(4):732-740. PubMed ID: 37522622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.